亚砷酸联合反应停、维生素C治疗难治性复发性多发性骨髓瘤疗效观察

Observation on the Clinical Effect of Arsenic Trioxide Combined with Thalidomide,Vitamin C in the Treatment of Refractory Relapse oMultiple Myeloma

目的:探讨亚砷酸联合反应停、维生素C治疗难治性复发性多发性骨髓瘤的临床疗效。方法:选取2003年3月-2013年4月本院收治的84例多发性骨髓瘤患者作为观察对象,随机分为治疗组43例和对照组41例,对照组采用常规疗法MP方案(马法兰+泼尼松),治疗组采用亚砷酸联合反应停、维生素C综合疗法,比较两组总有效率,并分别于治疗前后观察血象、骨髓象、肾功能、血清单克隆免疫球蛋白、血沉等指标,对比治疗前后各项指标的变化。结果:治疗组临床总有效率为83.7%,明显优于对照组的58.1%(P<0.05);且治疗组血象、骨髓象、肾功能、血清单克隆免疫球蛋白、血沉等指标改善明显优于对照组(P<0.05)。结论:亚砷酸联合反应停、维生素C治疗难治性复发性多发性骨髓瘤患者疗效显著,能提高患者生活质量,值得临床推广应用。

Objective：To investigate the clinical efficacy of arsenious acid,vitamin C combined with thalidomide in treatment of relapsed and refractory multiple myeloma. Method：84 patients with multiple myeloma selected from March 2003 to April 2013 in our hospital were as study objects,and were randomly divided into treatment group 43 cases and control group 41 cases,control group with conventional therapy scheme MP （melphalan＋prednisone）,treatment group were treated with arsenic trioxide combined thalidomide,vitamin C synthesis therapy,compared the total efficiency of two groups,and were observed in blood,bone marrow,renal function,serum monoclonal immunoglobulin,erythrocyte sedimentation rate and other indicators before and after treatment,changes of various indexes were compared before and after the treatment. Result：The total effective rate in the treatment group was 83.7%,significantly better than the control group 58.1%（P〈0.05）;and the patients in the treatment group blood,bone marrow, renal function,serum monoclonal immunoglobulin,erythrocyte sedimentation rate and other indicators improved significantly better than the control group （P〈0.05）. Conclusion：Arsenic trioxide combined with thalidomide,vitamin C in the treatment of refractory and relapsed multiple myeloma patients with obvious curative effect,can improve the quality of life of patients,is worthy of clinical application.